Guardant Health Announces Upsized Public Offering and Convertible Notes Offering

Details

announced an upsized public offering of 3,833,332 shares of common stock at $90.00 per share, with net proceeds expected to be approximately $327.2 million, and a private offering of $402.5 million aggregate principal amount of 0.00% Convertible Senior Notes due 2033, with net proceeds expected to be approximately $390.0 million. Both offerings were priced on November 5, 2025, and closed on November 7, 2025. The Company expects to use the net proceeds for general corporate purposes, potentially including repurchasing a portion of its 0% convertible senior notes due 2027.

Items reported

About Guardant Health Inc.

Guardant Health Inc. is an innovative biotechnology company specializing in the development and commercialization of precision oncology diagnostics. This company is recognized for its groundbreaking work in non-invasive cancer detection through liquid biopsy technologies, which involve analyzing circulating tumor DNA in blood samples. Guardant Health’s primary function is to provide oncologists and researchers with critical tools and data to better understand cancer, tailor treatments, and monitor disease progression, potentially improving patient outcomes significantly. Guardant Health operates prominently in the healthcare and biotechnology sector, significantly impacting fields such as cancer research and personalized medicine. Their products and services are vital for facilitating early detection of cancer, identifying treatment options, and offering companion diagnostics for pharmaceutical developments. In the financial market, Guardant Health represents an important player within the precision medicine landscape, influencing investment within the biotechnology and healthcare sectors. Founded in 2012 and headquartered in Redwood City, California, the company continues to expand its portfolio and advance its technologies, playing a pivotal role in the fight against cancer at a global level.